Multiple Endocrine Neoplasia Type 2A (MEN2A)

Multiple Endocrine Neoplasia Type 2A (MEN2A) is a rare inherited condition that affects the body's hormone-producing glands. It mainly involves the thyroid gland, adrenal glands, and parathyroid glands. People with MEN2A have a higher risk of developing certain types of tumors, including a cancer of the thyroid called medullary thyroid carcinoma. The condition can also cause tumors in the adrenal glands called pheochromocytomas, which affect blood pressure. Additionally, it may lead to overactivity of the parathyroid glands, causing problems with calcium levels in the body. MEN2A is caused by changes in a specific gene that controls cell growth in these glands.

Multiple Endocrine Neoplasia Type 2A (MEN2A) is an autosomal dominant syndrome characterized by the development of medullary thyroid carcinoma, pheochromocytomas, and primary hyperparathyroidism. It results from germline mutations in the RET proto-oncogene, which encodes a receptor tyrosine kinase involved in cell signaling and growth. The syndrome is clinically significant due to the high penetrance of aggressive medullary thyroid cancer and the potential for life-threatening pheochromocytoma-induced hypertension. Patients often present with symptoms related to hormone excess or mass effects from tumors. Early identification is critical for management and prevention of complications. Genetic testing for RET mutations is essential for diagnosis and family screening.